Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ACADIA Pharmaceuticals Inc before investing.

In this article, we go over a few key elements for understanding ACADIA Pharmaceuticals Inc’s stock price such as:

• ACADIA Pharmaceuticals Inc’s current stock price and volume
• Why ACADIA Pharmaceuticals Inc’s stock price changed recently
• Upgrades and downgrades for ACAD from analysts
• ACAD’s stock price momentum as measured by its relative strength

About ACADIA Pharmaceuticals Inc (ACAD)

Before we jump into ACADIA Pharmaceuticals Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. Its clinical-stage development are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis and neuropsychiatric symptoms in central nervous system disorders. Its pipeline includes NUPLAZID, Trofinetide, ACP-204 and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a treatment for Parkinson's Disease Psychosis. Trofinetide is a treatment for Rett Syndrome. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. ACP-204 is a treatment for Alzheimer’s Disease Psychosis. It also owns rights to NNZ-2591 in both Rett and Fragile X syndrome.

Want to learn more about ACADIA Pharmaceuticals Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc’s Stock Price as of Market Close

As of December 06, 2023, 4:00 PM, CST, ACADIA Pharmaceuticals Inc’s stock price was $21.38.

ACADIA Pharmaceuticals Inc is down 4.08% from its previous closing price of $22.29.

During the last market session, ACADIA Pharmaceuticals Inc’s stock traded between $22.18 and $22.70. Currently, there are 164.23 million shares of ACADIA Pharmaceuticals Inc stock available for purchase.

Unfortunately, ACADIA Pharmaceuticals Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

ACADIA Pharmaceuticals Inc Stock Price History

ACADIA Pharmaceuticals Inc’s (ACAD) price is currently down 4.04% so far this month.

During the month of December, ACADIA Pharmaceuticals Inc’s stock price has reached a high of $23.06 and a low of $21.20.

Over the last year, ACADIA Pharmaceuticals Inc has hit prices as high as $33.99 and as low as $14.45. Year to date, ACADIA Pharmaceuticals Inc’s stock is down 8.4%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused ACADIA Pharmaceuticals Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 05, 2023, there was 1 analyst who downgraded ACADIA Pharmaceuticals Inc’s stock and 15 analysts who upgraded over the last month.

Additionally, you'll want to evaluate ACADIA Pharmaceuticals Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on ACADIA Pharmaceuticals Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

ACADIA Pharmaceuticals Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about ACADIA Pharmaceuticals Inc (ACAD) by visiting AAII Stock Evaluator.

Relative Price Strength of ACADIA Pharmaceuticals Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 05, 2023, ACADIA Pharmaceuticals Inc has a weighted four-quarter relative price strength of 3.51%, which translates to a Momentum Score of 77 and is considered to be Strong.

Want to learn more about how ACADIA Pharmaceuticals Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

ACADIA Pharmaceuticals Inc Stock Price: Bottom Line

As of December 6, 2023, ACADIA Pharmaceuticals Inc’s stock price is $21.38, which is down 4.08% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like ACADIA Pharmaceuticals Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.